Mustang Bio, Inc. (MBIO)
NASDAQ: MBIO · Real-Time Price · USD
1.240
-0.089 (-6.70%)
At close: Apr 24, 2025, 4:00 PM
1.220
-0.020 (-1.61%)
After-hours: Apr 24, 2025, 7:10 PM EDT
Company Description
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases.
It develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-101, an IL13Ra2 CAR T cell program for glioblastoma; and MB-108 for the treatment of herpes simplex virus-1 oncolytic virus C134.
The company was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Mustang Bio, Inc.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Manuel Litchman |
Contact Details
Address: 95 Sawyer Road, Suite 110 Waltham, Massachusetts 02453 United States | |
| Phone | (781) 652-4500 |
| Website | mustangbio.com |
Stock Details
| Ticker Symbol | MBIO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001680048 |
| CUSIP Number | 62818Q104 |
| ISIN Number | US62818Q2030 |
| Employer ID | 47-3828760 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Manuel Litchman M.D. | President, Chief Executive Officer, Interim Chief Financial Officer and Director |
| Michael S. Weiss Esq. | Executive Chairman |
| Peter Carney | Controller and Interim Chief Accounting Officer |
| Greg Furrow M.S. | Chief Quality Officer |
| Robyn M. Hunter | Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 11, 2025 | EFFECT | Notice of Effectiveness |
| Apr 4, 2025 | POS AM | Post-Effective amendments for registration statement |
| Apr 2, 2025 | SCHEDULE 13D/A | Filing |
| Apr 1, 2025 | POS EX | Filing |
| Apr 1, 2025 | 424B3 | Prospectus |
| Mar 28, 2025 | 10-K | Annual Report |
| Mar 5, 2025 | 8-K | Current Report |
| Mar 3, 2025 | DEF 14C | Filing |
| Feb 27, 2025 | 424B3 | Prospectus |
| Feb 27, 2025 | 8-K | Current Report |